London-based IMU Biosciences has announced that its Series A financing exceeded $53 million in an oversubscribed round, bringing the company’s total funding to $60 million to date.
The round was co-led by IQ Capital and Molten Ventures, with participation from The British Business Bank, Meltwind, and existing investors. IMU Biosciences is developing an immune profiling platform that combines multi-omic analysis and machine learning to measure the immune system from a blood sample.
The company said the new capital will be used for operational expansion, clinical platform and infrastructure development, and to advance programmes in stem cell transplant, solid organ transplant, and MANIFEST, a UK research consortium studying patient responses to cancer immunotherapies.
The raise underscores continued investor interest in biotech platforms using large-scale biological data and AI to support precision medicine and clinical decision-making.
The round was co-led by IQ Capital and Molten Ventures, with participation from The British Business Bank, Meltwind, and existing investors. IMU Biosciences is developing an immune profiling platform that combines multi-omic analysis and machine learning to measure the immune system from a blood sample.
The company said the new capital will be used for operational expansion, clinical platform and infrastructure development, and to advance programmes in stem cell transplant, solid organ transplant, and MANIFEST, a UK research consortium studying patient responses to cancer immunotherapies.
The raise underscores continued investor interest in biotech platforms using large-scale biological data and AI to support precision medicine and clinical decision-making.